216 related articles for article (PubMed ID: 22302767)
1. Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.
Cumella J; Hernández-Folgado L; Girón R; Sánchez E; Morales P; Hurst DP; Gómez-Cañas M; Gómez-Ruiz M; Pinto DC; Goya P; Reggio PH; Martin MI; Fernández-Ruiz J; Silva AM; Jagerovic N
ChemMedChem; 2012 Mar; 7(3):452-63. PubMed ID: 22302767
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.
Rahn EJ; Thakur GA; Wood JA; Zvonok AM; Makriyannis A; Hohmann AG
Pharmacol Biochem Behav; 2011 Jun; 98(4):493-502. PubMed ID: 21382397
[TBL] [Abstract][Full Text] [Related]
3. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
4. CB2 cannabinoid receptor-mediated peripheral antinociception.
Malan PT; Ibrahim MM; Deng H; Liu Q; Mata HP; Vanderah T; Porreca F; Makriyannis A
Pain; 2001 Sep; 93(3):239-245. PubMed ID: 11514083
[TBL] [Abstract][Full Text] [Related]
5. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
7. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
8. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptors and pain.
Pertwee RG
Prog Neurobiol; 2001 Apr; 63(5):569-611. PubMed ID: 11164622
[TBL] [Abstract][Full Text] [Related]
10. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
[TBL] [Abstract][Full Text] [Related]
11. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid receptor agonists from Conus venoms alleviate pain-related behavior in rats.
Jergova S; Perez C; Imperial JS; Gajavelli S; Jain A; Abin A; Olivera BM; Sagen J
Pharmacol Biochem Behav; 2021 Jun; 205():173182. PubMed ID: 33774007
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
16. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
[TBL] [Abstract][Full Text] [Related]
17. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Kinsey SG; Mahadevan A; Zhao B; Sun H; Naidu PS; Razdan RK; Selley DE; Imad Damaj M; Lichtman AH
Neuropharmacology; 2011; 60(2-3):244-51. PubMed ID: 20849866
[TBL] [Abstract][Full Text] [Related]
18. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
19. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]